Compounding Pharmacies Jump on Shortage Opportunity In 2022, the FDA added Eli Lillys Zepbound and Novo Nordisks Wegovyalong with their sister GLP-1s for diabetes, Mounjaro and Ozempic, respectivelyto its list of drugs in shortage, opening the door for compounding pharmacies to legally produce compounded versions for patients who were not able to source branded products
The primary endpoint was BMD change at the femoral neck and lumbar spine after 12 months
Copyright: 1993 Edition Lonza, LONZA Ltd
They are picky about what they bring into the plant
Wakabayashi T, Hidaka R, Fujimaki S, Asashima M, Kuwabara T
Clinical trials are also exploring GLP-1s for conditions like MASH, Alzheimer's disease, and alcohol use disorder